Wilkes University

Faculty

Contact Information


profile

Dr.Ajay Bommareddy

Associate Professor, Pharmaceutical Sciences

Location: Stark Learning Center
Email:ajay.bommareddy@wilkes.edu
Phone: 570-408-4220

Learn more about Dr. Ajay Bommareddy


Dr. Abel Adekola

Dr. Ka Lok Hong

Assistant Professor, Pharmaceutical Sciences

Location:150-180 South River Street, 319 A
Email:kalok.hong@wilkes.edu
Phone: 570-408-4296

Learn more about Dr. Ka Lok Hong


profile

Dr. Adam L. VanWert

Associate Professor, Pharmaceutical Sciences

Location:Stark Learning Center
Email:adam.vanwert@wilkes.edu
Phone: 570-408-4336

Learn more about Dr. Adam L. VanWert


Dr. Abel Adekola

Dr. Zbigniew J. Witczak

Professor, Pharmaceutical Sciences

Location:Stark Learning Center
Email:zbigniew.witczak@wilkes.edu
Phone: 570-408-4276

Learn more about Dr. Zbigniew J. Witczak


Experts Serving on the Advisory Board for the Master’s Program

profile

Allen B. Reitz, Ph.D.

Chief Executive Officer
Fox Chase Chemical Diversity Center, Inc., Doylestown, PA

Education:
  • Ph.D., Chemistry, University of California, San Diego
  • Executive Masters in Technology Management, University of Pennsylvania (Wharton, Penn Engineering)

Current Professional Roles

  • Chief Executive Officer, Fox Chase Chemical Diversity Center, Inc.
  • Chief Executive Officer, ALS Biopharma, LLC
  • Adjunct Professor, Drexel University College of Medicine
  • Founding Editor and Editor-in-Chief, Current Topics in Medicinal Chemistry
  • Editorial Advisory Board, ACS Medicinal Chemistry Letters

Past Professional Experience

  • Medicinal Chemist at Johnson & Johnson for 26 years, Spring House, PA

Dr. Reitz is a leading scientist in his field. He was born in Alameda, California U.S.A. in 1956. He obtained his Ph.D. at the age of 25 in Chemistry from the University of California, San Diego. His thesis advisor, the late Professor Murray Goodman, was a prominent peptide and synthetic organic chemist who inspired and encouraged Dr. Reitz towards a scientific career. Dr. Reitz has >160 peer-reviewed publication, and is an inventor on 68 issued U.S. patents. He led the teams that invented mazapertine and troriluzole, the latter of which is currently in 5 separate clinical trials, and is a co-inventor of VK-2019, currently in clinical trials for the treatment of nasopharyngeal carcinoma. Dr. Reitz founded Fox Chase Chemical Diversity Center, Inc. (FCCDC, www.fc-cdci.com) in 2008. FCCDC is an emerging biotechnology company in the Philadelphia area employing ~25 medicinal chemists and pharmacologists.

Dr. Reitz is interested in synthetic organic chemistry, chemical biology, early-stage drug discovery target validation, hit to lead medicinal chemistry, lead optimization medicinal chemistry and pre-IND enabling activities. He performed seminal research on the mechanism of the Wittig reaction, with over 2,200 citations of the article “The Wittig olefination reaction and modifications involving phosphoryl-stabilized carbanions. Stereochemistry, mechanism, and selected synthetic aspects.” He also co-authored Vol. 59 of “Organic Reactions”, a >700-page work on reductive aminations using boron-containing agents.

View many of Dr. Reitz’s publications on Google Scholar

profile

Roman Bielski,Ph.D.

Senior Chemist, Value Recovery
Co-founder, Cheminnolab and several other companies
Adjunct Professor

Education:
  • M.Sc, Chemical Engineering, Warsaw Institute of Technology (Poland)
  • Ph.D., Organic Synthesis, Polish Academy of Sciences, Inst. Organic Chem (Poland)
Post-Graduate Training:
  • Postdoctoral Fellow, Organic Chemistry, Imperial College (London)

2016 - pres.Biosynthon, Inc. development of novel encapsulation technology.

2012 - pres. Chemventive, LLC. consulting; several awards from Innocentive and Nine Sigma. 

2010 - pres. Wilkes University, Dept. of Pharmaceutical Sciences, Adjunct Professor.

2006 - 12Cheminnolab, LLC., partnership developing green technologies; Co-Founder and one of four principals.

2002 - 09Value Recovery, Inc., small company developing environmental technologies; Chief Technology Officer. 

1999 - 02PetrAmec, Inc., small company devoted to microencapsulation processes for petroleum and food industries; Co-Founder, President and Principal Scientist.

1995 - 99PetroTraces, Inc., company developing ultra-sensitive measurements in the petroleum industry; Co-Founder, R&D Manager and Principal Scientist.

1993 - 97AttoChrom/BioTraces, Inc., small biotech firm using ultra-sensitive detection (MPD) to bioassays; Senior Research Scientist.

1988 - 92Dept. of Chemistry, Cornell University, development of new applications of novel Exxon polymers; Senior Research Associate.

1987 - 88Dept. of Chemistry, Lehigh University, synthesis of new calixarenes and their application to separation of gases; Visiting Professor. 

1978 - 87Warsaw Agricultural University, teaching organic chemistry (class and lab) and total syntheses of pheromones, Assistant Professor.

1974 - 76Institute of Education, Adjunct Researcher, application of models in teaching stereochemistry.

Dr. Roman Bielski is a chemist with expertise in the synthesis and modification of macromolecules and radio-labeled compounds, surface chemistry, ultra-sensitive measurements in petroleum products, biological fluids, and food, coupling and decoupling of molecules for medicinal chemistry applications, total synthesis of carbohydrates and pheromones, formation of micro/nanocapsules for controlled delivery and chirality.

Dr. Bielski holds a Masters degree in chemical engineering and a Ph.D. in organic chemistry (with O. Achmatowicz of the Achmatowicz reaction) (from the Institute of Organic Chemistry, Polish Academy of Sciences). He was a post doctoral fellow at Imperial College in London with the Nobel laureate Sir Derek Barton. He worked in academia at Warsaw Agricultural University, Cornell University, Lehigh University.

Dr. Bielski co-founded several small companies (Petramec, Petrotraces, Attochrom/ Biotraces, Cheminnolab, Biosynthon). At present, he is one of two principals in Chemventive, LLC, and Biosynthon, Inc. and an Adjunct Professor at Wilkes University. Working in Value Recovery Dr. Bielski developed a novel technology enabling the recovery of various waste components (using phase transfer catalysis) and a method to economically destroy major ozone deplete, methyl bromide. He is a member (chair 2015-16) of the Chemical Consultants Network and working with various clients developed a novel method to transform used tires into fuels, cellulosic waste materials into hydroxymethylfurfural (HMF) and a novel material formulation for a disposable oral hygiene product based on cross-linked gelatin.

Dr. Bielski (with M. Tencer) has discovered a novel chiral influence and developed a method to resolve racemates without using chiral compounds (absolute enantioselective separation {AES}). The method has been described in 6 publications and a few invited presentations. The concept offers a plausible answer to the origin of homochirality problem and explains why ribose is a sugar component of nucleic acids. Recently (together with Z.J. Witczak), he discovered a method offering a major expansion of the Claisen rearrangement.

He authored or co-authored almost four dozen academic publications and holds close to 20 patents, with several pending applications and a few patents in a pipeline. 5 years ago, he published (Chemical Reviews) a seminal paper offering a novel strategy of connecting and disconnecting molecules. He is a reviewer for several journals including Journal of Organic Chemistry, Catalysis Communications, Organic Processes Research and Development, Polymer International, Journal of Fluorine Chemistry, Letters in Organic Chemistry, and Journal of Chemical Technology and Biotechnology.

Phase 1 and 2 SBIR grants from DoE, phase 1 SBIR grants from USDA and EPA, Ben Franklin Technology Center grant (1995 - 2002), multiple Nine Sigma and Innocentive challenge awardee, Co-chair of the symposia “The click-chemistry approaches in carbohydrate chemistry” and “Domino and Intramolecular Rearrangement Reactions in Carbohydrate Chemistry” organized by the Carbohydrate Division of ACS. Co-editor and one of the authors of relevant books published by Wiley in 2013 and 2015. Co-Chair of the PACIFICHEM 2015 symposium “Coupling and decoupling of diverse molecular units in Glycoscience” organized in December 2015 in Honolulu and co-editor of a relevant book published by Springer. Chair of the Chemical Consultants Network (CCN) (2015-2016).

View Dr. Bielski’s publications on Google Scholar

profile

Dennis M. Gross, M.S., Ph.D., S.S.Y.B., S.F.C.

Chief Executive Officer and Treasurer
Professor of Pharmacology
Pennsylvania Drug Discovery Institute (PDDI), Doylestown, PA

Education:
  • Ph.D., Cell Biology, University of California, Los Angeles
  • M.S., Biology, California State University Northridge
  • B.A., Biology; Minor, English; California State University Northridge
  • Strategic Management Program, The Wharton School at the University of Pennsylvania
  • Program on Negotiation for Senior Executives: Harvard Law School, MIT and Tufts University
  • Program in Fundamentals of Finance for Technical Executives, MIT Sloan School of Management

Current Professional Roles

  • CEO & Treasurer/Secretary, Professor of Pharmacology, Pennsylvania Drug Discovery Institute, Doylestown, PA
  • Professor (with Distinction) of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute of the Hepatitis B Foundation, Doylestown, PA
  • Faculty, Jefferson College of Life Sciences and Adjunct Associate Professor of Pharmacology and Experimental Therapeutics, the Sidney Kimmel Medical College of Jefferson University, Philadelphia, PA
  • Adjunct Professor of Basic Science in the Department of Basic Sciences, The Geisinger Commonwealth School of Medicine, Scranton, PA
  • Corporate Faculty, Harrisburg University of Science & Technology, Harrisburg, PA
  • Life Sciences Pennsylvania State Government Policy Committee
  • Local Co-Chair [2014-15] and National Co-Chair [2015-] BIO Biotechnology Entrepreneurship Boot Camp
  • Managing Director, The DMG Consultancy LLC, Gwynedd Valley, PA

Past Professional Experience

  • 2013-2014 
    • Associate Dean, Program Development and Assessment, Director for the PSM Master’s Degree Program in Biomedical Sciences and Associate Director, Postbaccalaureate Pre-Professional Program (P4), Jefferson Graduate School of Biomedical Sciences, Thomas Jefferson University, Philadelphia, PA
    • Associate Professor of Pharmacology and Experimental Therapeutics, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA

Areas of Activities

        • Management of MS program in Biomedical Sciences and and Graduate Certificate program in Clinical Trials Management
        • Postbaccalaureate Pre-Professional Program
        • Strategic Planning and Outcomes Assessment
        • Recruiting, Career Counseling and Guidance
        • IT and Distance Learning Issues
        • Emergency Preparedness, Response & Business Continuity
  • 2010
    • Chief Scientific Officer, New Jersey Natural Therapeutics, Flemington, New Jersey
  • 2006-2013
    • Associate Dean and Director, Professional Science Master’s Degree and Graduate Certificate Programs, Jefferson College of Graduate Studies, Thomas Jefferson University, Philadelphia, PA.
    • Associate Professor of Pharmacology and Experimental Therapeutics, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA

Areas of Activities

      • Management of MS programs in Biomedical Sciences, Pharmacology, Microbiology, Cell & Developmental Biology and Graduate Certificate programs
      • Strategic Planning
      • Recruiting, Career Counseling and Guidance
      • IT and Distance Learning Issues
      • Emergency Preparedness, Response& Business Continuity
  • 2009-2015
    • Guest Lecturer: Drexel University College of Medicine Laboratory Animal Management II – Facilities Design MLAS 521S 01
  • 2009-2011
    • Guest Lecturer: College of New Jersey School of Business:

Lecture Topics: FDA Drug Law and CFR 21

  • 2005-2006
    • Senior Director and Head of Business Operations & Planning, MRL Research Operations, Merck Research Labs, West Point, PA

Areas of Activities

        • Strategic Operations Planning
        • Facilities Management and Supervision of Managers at Wayne, North Wales and Blue Bell, PA, and San Diego research and office facilities
      • Financial Management (Capital and Expense Budgets) for Basic Research (West Point) and Preclinical Development (West Point and Rahway)
      • Sarbanes-Oxley Compliance
      • Capital Construction Projects at West Point and North Wales, PA
      • Site Decommissioning
      • Emergency Preparedness and Response, Business Continuity Planning
      • Health Policy Issues
      • International BWC Inspection and Compliance Issues
  • 1986-2005
    • Adjunct Associate Professor, Department of Biochemistry and Molecular Pharmacology, Jefferson Medical College, College of Graduate Studies and the Center for Graduate Education and Training, Thomas Jefferson University, Philadelphia, PA
  • 2005
    • Director, Business Operations & Planning, Research Operations, Merck Research Laboratories, West Point, PA

Areas of Activities

      • Strategic Operations Planning
      • Facilities Management and Supervision of Managers at Wayne, North Wales and Blue Bell, PA, and San Diego labs
      • Financial Management (Capital and Expense Budgets)
      • Capital Construction Projects at West Point and North Wales, PA, and at Terlings Park and Hoddesdon (UK).
      • Sarbanes-Oxley Compliance
      • Site Decommissioning (Tarrytown, NY and La Jolla, California)
      • Emergency Preparedness and Response
      • Health Policy Issues
      • International BWC Inspection and Compliance Issues
  • 2004
    • Director, Investment Analysis & Planning, Research Operations, Merck Research Laboratories (MRL). West Point, PA

Areas of Activities

      • Project Administrator for MRL-Boston Research Center Lab Construction Project
      • Strategic Operations Planning
      • Sarbanes-Oxley Compliance
      • Emergency Preparedness and Response
      • Health Policy Issues & International BWC Inspection Issues
      • Capital Projects: Montreal (Canada), Terlings Park and Hoddesdon (UK), West Point, Wayne& North Wales (PA)
  • 1999- 2003
    • Adjunct Professor of Global Logistics, School of Business and Industry, Florida A&M University, Tallahassee, Florida

Areas of Activities

      • Lectures in Competitive Intelligence, Strategic Planning, and Industry Case Studies
      • Graduate student advising
  • 1998-2003
    • Director, Program Resources and Logistics, Worldwide Strategic and Capital Planning, Merck Research Laboratories (MRL). West Point, PA and Boston, MA

Areas of Activities

      • Project Administrator for MRL-Boston Research Center Lab Construction Project
      • Strategic Operations Planning
      • Capital Projects: Montreal (Canada), Terlings Park and Hoddesdon (UK), Rome (IT), West Point and North Wales (PA), La Jolla (CA)
  • 1992-1998
    • Director, Program Resources and Logistics, Worldwide Basic Research Administration, Merck Research Laboratories. West Point, PA and Rahway, NJ

Areas of Activities

      • Research administration for WP Basic Science departments
      • Strategic Operations Planning
      • Basic research and clinical research liaison to Banyu (Japan)
      • Operations oversight at Banyu Labs and IRBM (Rome)
      • Site Decommissioning (Lawrence, Kansas)
  • 1990-1991
    • Associate Director, International Strategic and Scientific Planning, Biomedical Research Administration, Merck Sharp & Dohme Research Laboratories, West Point, PA

Areas of Activities

      • Member of capital project teams for new labs in Rome (Italy) and Tsukuba Science City (Japan)
      • Competitive Intelligence
      • Research Administration & Planning
  • 1990
    • Associate Director, External Scientific Affairs & Licensing, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey

Areas of Activities

      • Manager of Academic Development Postdoctoral Grant Program
      • Managed Postdoctoral MD/Ph.D. Fellowship Program jointly with the American Federation for Clinical Research
  • 1988-1998
    • Visiting Lecturer in Global Logistics, School of Business and Industry, Florida A&M University, Tallahassee, Florida.
      • Lecture Topics: Strategic Planning and Competitive Intelligence
  • 1987-1989
    • Manager of Strategic Planning and Divisional Computer & Data Security Administrator, Department of Information Resources & Strategic Planning, Merck Sharp & Dohme Research Laboratories, Rahway, NJ

Areas of Activities

      • Scientific Strategic Planning
      • Information Resources Strategic Planning
      • Merger & Acquisition Assessments
      • Competitive Intelligence
  • 1982-1986
    • Research Fellow and Divisional Computer & Data Security Administrator, Department of Computer Resources, Merck Sharp & Dohme Research Laboratories, West Point, PA

Areas of Activities

      • Data & Computer Security, Lab Automation
      • Animal Compliance Assurance Committee
  • 1981-1982
    • Research Fellow, Cardiovascular Section, Department of Pharmacology, Merck Institute for Therapeutic Research and MSDRL, West Point, PA.

Research Interests

      • Research and development of new drugs for hypertension and the renal/cardiovascular system
      • Biomedical computer and lab automation applications
      • Animal Compliance Assurance Committee
  • 1979-1987
    • Radiation Safety Supervisor and Officer, Department of Health Physics, MSDRL and Merck Sharp & Dohme Manufacturing Divisions

Function

      • Approval of purchase requests for isotopes
      • Supervision of isotope use in labs and use of cobalt and cesium irradiators
      • Development of training programs for safe isotope use in a lab environment
  • 1977-1986
    • Adjunct Assistant Professor of Pharmacology, Department of Pharmacology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
  • 1977-1981
    • Senior Research Pharmacologist, Cardiovascular Section, Merck Institute for Therapeutic Research, West Point, PA

Research Interests

        • Angiotensin converting enzyme inhibitors for hypertension
        • Vasodilators for renal failure
        • β-adrenergic blockers for ocular hypertension
        • Cardioselective β-adrenergic blockers for hypertension
  • 1976-1977
    • Instructor in Pharmacology, Department of Pharmacology, School of Medicine, Tulane University Medical Center, New Orleans, LA
  • 1974-1977
    • Postdoctoral Research Fellow, National Heart, Lung and Blood Institute Hematopharmacology Training Grant, Department of Pharmacology and the Laboratory of Hematopharmacology, School of Medicine, Tulane University Medical Center, New Orleans, LA
      • Research Interest: Cellular pharmacology and physiological factors controlling erythropoietin production and erythropoiesis in man and animals.
  • 1973-1974
    • Head Teaching Fellow, Department of Biology, University of California, Los Angeles.
  • 1972-1973
    • Postgraduate Research I,II and Staff Research Associate Department of Biology, U.C.L.A.
      • Research Interest: Cell biology of the kidney in health and disease
  • 1971-1974
    • Applications and Engineering Consultant for Ivan Sorvall, Inc., Newtown and Norwalk, CT.

Fields

        • Electron microscopy
        • Ultracentrifugation
        • Zonal density gradient centrifugation- rotor design and applications.
  • 1971-1972
    • Teaching Assistant and Teaching Associate, Department of Zoology, U.C.L.A.
  • 1971-1972
    • Research Assistant, Department of Zoology, U.C.L.A.
      • Research Interest: Ultrastructural morphology and histochemistry of the juxtaglomerular apparatus of the mammalian kidney.
  • 1969-1970
    • Graduate Assistant and Research Assistant, Department of Biology, California State University, Northridge
      • Research Interest: Ultrastructural morphology and cellular physiology of the encystment process of the quadraflagellated protozoan Polytomella agilis
  • 1968
    • Summer Research Fellow of the California Foundation for Biochemical Research, Department of Biology, California State University, Northridge
      • Research Interest: Studies on DNA synthesis in synchronized zygotes of the seaweed Fucus distichus
  • 1965-66
    • Medical Photographer Trainee, Academic Communications Facility, U.C.L.A. Center for the Health Sciences, Los Angeles, CA

The tables on this website are converted with the Div Table online tool. Please subscribe for an online HTML editor membership to stop adding promotional messages to your documents.

Dr. Dennis Gross is the CEO and Professor of Pharmacology at the Pennsylvania Drug Discovery Institute (PDDI) in Doylestown. The PDDI is a 501 (c)(3) organization that provides services to the scientific community in the region. His activities include management of the PDDI, redistribution of donated lab materials, STEAM education initiatives, fund-raising and national co-chair of the Biotechnology Entrepreneurs’ Boot Camp held in association with the International BIO meeting. He is also Professor (with Distinction) of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute of the Hepatitis B Foundation, Faculty in the Jefferson College of Life Sciences and Adjunct Associate Professor of Pharmacology in the Sidney Kimmel Medical College at Thomas Jefferson University, Adjunct Professor of Basic Science in the Department of Basic Science at The Geisinger Commonwealth School of Medicine and Corporate Faculty at Harrisburg University of Science and Technology. He has also a Member of the Northeast Biomanufacturing Center and Collaborative National Visiting Committee and a member of the Life Sciences PA State Government Policy Committee.

Dr. Gross received his B.A. (1969) and M.S. (1970) at the California State University at Northridge working in analytical biochemistry and the development of a new type of zonal centrifuge rotor that was marketed by Ivan Sorvall, Inc. His doctoral research was undertaken in cell biology and electron microscopy at U.C.L.A. where his Ph.D. was granted in 1974 for work on the isolation and characterization of renin-containing granules. During this period, he also worked as an applications engineering consultant for Ivan Sorvall, Inc. on product issues for cell separation and electron microscopy. His Postdoctoral work was pursued in the Department of Pharmacology at Tulane University School of Medicine in New Orleans on a NIH Hematopharmacology training grant. Dr. Gross worked on the control of erythropoietin production and the mechanisms of the anemia of renal insufficiency. He was also an Instructor in the Department of Pharmacology and lectured in both the medical and graduate schools. At Tulane, he was the recipient of a grant from the American Heart Association and was awarded a Young Investigators Career Development Award from the NIH Heart, Lung and Blood Institute for work on erythropoietin control mechanisms.

Dr. Gross began his professional career at the Merck Sharp & Dohme Research Labs and the Merck Institute for Therapeutic Research at West Point, PA in 1977 as a Senior Research Pharmacologist. He worked on the project team that discovered the angiotensin converting enzyme inhibitors VASOTEC® (Enalapril) and PRINIVIL® (Lisinopril). He also conducted research on new therapeutic agents to treat glaucoma, kidney and heart failure. During this period, he was also the Radiation Safety Officer for the West Point site with responsibility for both the research and the manufacturing division and a member of the animal compliance assurance inspection team with responsibility for all primates on site. In 1982, Dr. Gross helped start the MSDRL Department of Computer Resources as manager and served as the

Divisional Computer and Data Security Administrator for the entire research division worldwide. In 1987, he became the Manager of Strategic Planning for the research labs and moved to Rahway, New Jersey. While in Rahway, he was also assigned to Merck Corporate Finance as a member of an interdivisional M&A team charged with the evaluation of potential merger candidates. In 1990 he moved back to West Point as Associate Director of International Strategic and Scientific Planning while simultaneously pursuing a temporary assignment in Rahway in the Department of External Scientific Affairs directing external fellowship and postdoctoral grant programs. During this period, he was also a member of the capital project teams involved with business negotiations and coordination of the design, programming,

construction and occupancy of new joint venture research laboratories in Tsukuba (Japan) and Rome (Italy). As a continuation of the assignment in Japan, he became the lead for basic and clinical research liaison to the Banyu Research Labs in Tokyo and Tsukuba spending more than 12 years working with the Merck Japanese subsidiary. In addition, he served for 6 years as the Executive Secretary for the cross-divisional Marketing and Research Development Coordination Committee (DCC) that oversaw all clinical development and research activities worldwide from Phase II through post marketing Phase V trials.

In 1992, Dr. Gross moved to the Department of Worldwide Basic Research Administration and directed research administration at West Point while continuing his liaison role in Japan and continuing to serve as Executive Secretary for DCC. In 1998, he transferred to the Department of Worldwide Strategic & Capital Planning as Director of Program Resources and Logistics. He was primarily involved with the geographically distributed laboratories and strategic planning for divisional resources. In that role, he was responsible for negotiating external material transfer agreements, operations and financial oversight at Merck’s research labs in Montreal, San Diego, Terlings Park (UK), Tsukuba (Japan) and Rome. This activity also involved leading or being a member of capital project teams engaged in lab and office renovations or new construction at West Point, a 45,000 GSF addition to the labs in Italy that included vivarium space, a 40,000 GSF pharmacology and vivarium building in Montreal, a 90,000 GSF vivarium and transgenic support facility plus new combinatorial chemistry labs and support facilities at

Terlings Park (UK) and new pharmaceutical R&D facilities in Hoddesdon, UK. As part of these expansion activities, he also was responsible for organizational and operations assessments at the overseas labs in Japan and Italy. These assessments resulted in significant organizational and structural realignment of the labs and their research programs and operations.

His last major capital project assignments at MRL were for a 147,000 GSF drug metabolism and pharmaceutical R&D building at West Point (2002-2005) and as project administrator and client (1998-2004) for a mid-rise (18 stories) 614,000 GSF basic research facility in Boston. In addition, he has worked with Merck’s Human Health division on public policy and governmental issues at the state level visiting with state legislators in Pennsylvania, Massachusetts and New Jersey. He was also a member of the first formal MRL mentoring program focused at recently hired bench scientists. While at Merck, Dr. Gross was also an Adjunct Associate Professor in the Department of Biochemistry and Molecular Pharmacology, Jefferson Medical College. He previously served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University in Tallahassee, Florida where he lectured on competitive intelligence and strategic planning. He has also worked with the Center for Strategic & International Studies in Washington, DC on policy issues and the development of site

inspection protocols relating to the production of biological weapons of mass destruction and compliance with the International Treaty on such weapons.

His last position prior to his retirement in 2006 from Merck was as Senior Director and Head of West Point Business Operations & Planning with responsibility for Basic Research, Pre-Clinical Development, Lab Services, and Facilities Management at West Point, North Wales, Blue Bell and Wayne, PA and San Diego, CA. In this capacity, he supervised 150 professional and unionized staff in support of over 1400 scientists, clinicians and research technicians and represented the research lab division on site-wide management committees and helped staff the emergency command center serving on call 24/7 in that role. In his role as Senior Director he was also the lead for task teams charged with downsizing strategic laboratory resources and facilities in San Diego and subsequently closing facilities in San Diego, Tarrytown (NY), Lawrence (KS), and Terlings Park (UK).

He joined Thomas Jefferson University fulltime in 2006 as the Associate Dean and Director of the MS programs in the University’s College of Graduate Studies. In his first role at Jefferson he was responsible for Professional Science MS degree programs (PSM) in biomedical sciences, cell and developmental biology, microbiology, and pharmacology. These MS degree programs were originally positioned as part-time degree programs to aid staff of the local DelVal biopharma industry achieve new skill sets to aid them in advancing their careers. He also directed graduate certificate programs in clinical esearch/trials, human clinical investigation and the control of infectious diseases in the Jefferson Center for Graduate Education and Training. He served on the School’s Graduate Council as Secretary, member of the Curriculum Committee and was a member of the IT Governance and Distance Learning Committees, the

Global Health Working Group, the University Emergency Preparedness Committee, and staffed the Emergency Command Center which also involved designing and leading tabletop emergency planning and business continuity exercises for the University. He also provided career counseling services for graduate students and postdoctoral fellows.

In 2012 his role at Jefferson changed to being Associate Dean for Program Development and Assessment responsible for the development of strategic and tactical plans for the development of new degree and graduate certificate programs and the development of new metrics and assessment tools for the MS and PhD programs. He was also the Associate Director for Curriculum and Administration for the new Post-Baccalaureate Pre-Professional Program where he also lectured in introductory biology and co-coordinated a course in the arts and humanities of medicine in addition to leading the project team that created new flexible teaching labs for the program. Additionally, he coordinated and lectured in graduate courses on drug discovery issues and research ethics. He also lectured in courses in lab animal

science, bioventure management, cell biology, clinical pharmacology, strategic management, and fundamentals of clinical trials. He was also Associate Professor of Pharmacology & Experimental Therapeutics in the Jefferson Medical College and lectured in the 4th year medical school elective course in clinical pharmacology.

He has also maintained a consultancy practice in the area of laboratory facility design and management working with several A&E and facility design firms. He is the Managing Director of The DMG Consultancy. Working with KlingStubbins, he authored the introductory chapter to a book published by Wiley on the design and operation of the sustainable laboratory building for the 21st century. He was also part of a project team bidding on designs for research and teaching labs at Georgia State University, Penn State University, and a new graduate university complex in Saudi Arabia. Working with KlingStubbins he was part of a group commissioned by a Cambridge-based pharma firm to help them “right size” their facilities in anticipation of being acquired. His last major consultancy project involved working with KlingStubbins, the Jacobs Consultancy, The Hay Group and RTKL in the development of an organizational structure, master site plans, facility design and bid documents for a 3,090,000 sq. foot site slated to house offices, support buildings and a lab complex for the Saudi Arabian FDA.

He has authored or co-authored over 100 scientific papers, abstracts and reviews. He is a member of the American Association for Pharmaceutical Scientists, American Chemical Society Medicinal Chemistry Division, The History of Science Society, International Society for Pharmaceutical Engineering, Lab Robotics Interest Group, Sigma Xi and SAPA-GP. He has also received certification from the FEMA Emergency Management Institute for NIMS/ICS training for Schools and Healthcare/Hospital facilities, certification in Scrum Fundamentals and is a Six Sigma Yellow Belt. In addition, he is co-editor of the journal Technology Transfer and Entrepreneurship and associate editor of the Journal of Commercial Biotechnology.

Research Papers

    1. Wells, J.R., Gross, D.M. and Sheeler, P. A large capacity reorienting density gradient zonal centrifuge rotor. Laboratory Practice 19: 497-499 (1970)
    2. Sheeler, P., Gross, D.M. and Wells, J.R. Zonal centrifugation in reorienting density gradients. BiochimicaBiophysicaActa 237: 28-42 (1971).
    3. Wells, J.R. and Gross, D.M. Batch and continuous-flow pelleting in the SZ-14 zonal rotor. Laboratory Practice 21: 182-183 (1972)
    4. Wells, J.R., Sheeler, P., and Gross, D.M. A reorienting density gradient rotor for zonal centrifugation. AnalyticalBiochemistry 46: 7-18 (1975)
    5. Gross, D.M. and Barajas, L. The large-scale isolation of renin-containing granules from rabbit renal cortex by zonal centrifugation. Journal of Laboratory and Clinical Medicine 85: 467-477 (1975)
    6. Gross, D.M., Mujovic, V.M., Jubiz, W. and Fisher, J.W. Enhanced erythropoietin and prostaglandin E production in the dog following renal artery constriction. Proceedings of the Society for Experimental Biology and Medicine 51:498-501 (1976)
    7. Ignarro, L.J., Gross, R.A. and Gross, D.M. Inhibition of mammalian soluble guanylate cyclase activity by adenosine 5'-tetra-phosphate, guanosine 5'-tetraphosphate and other nucleotides. Journal of Cyclic Nucleotide Research 2:337-346 (1976).
    8. Gross, D.M., Brookins, J., Fink, G.D. and Fisher, J.W. Effects of prostaglandins A2, E2 and F2α on erythropoietin production. Journal of Pharmacology and Experimental Therapeutics198: 489-496 (1976).
    9. Przala, F., Gross, D.M., Dargon, P.A. and Fisher, J.W. Effects of invitro beta-adrenergic activation on rabbit bone marrow erythroid colony forming cells. Proceedings of the Society for Experimental Biology and Medicine.155: 334-338 (1977).
    10. Gross, D.M. and Barajas, L. Studies on the characterization of isolated renin-containing granules: the storage form of renin. Journal of Medicine9: 53-66 (1978).
    11. Przala, F., Gross, D.M., Beckman, B. and Fisher, J.W. Influence of albuterol on erythropoietin production and erythroid stem cell activation. Haematologica 63: 395-404 (1978).
    12. Gross, D.M. and Fisher, J.W. Effects of terbutaline, a synthetic beta-adrenergic agonist, on invivo erythropoietin production. Archives Internationales de Pharmacodynamie et de Therapie. 236: 192-201 (1978).
    13. Foley, J.E., Gross, D.M., Nelson, P.K. and Fisher, J.W. The effects of arachidonic acid on erythropoietin production in exhypoxic polycythemic mice and the isolated perfused canine kidney. Journal of Pharmacology and Experimental Therapeutics. 207: 402-409 (1978).
    14. Nelson, P.K., Gross, D.M., Foley, J.E. and Fisher, J.W. A concept for the control of kidney production of erythropoietin: the role of prostaglandins and cyclic nucleotides. Haematologica 63: 629-646 (1978).
    15. Przala, F., Gross, D.M., Beckman, B. and Fisher, J.W. Influence of albuterol on erythropoietin production and erythroid progenitor cell activation. American Journal of Physiology 236: H422-H426 (1979).
    16. Sweet, C.S., Wenger, H.C. and Gross, D.M. Central antihypertensive properties of muscimol and related GABA agonists and the interaction of muscimol with baroreceptor reflexes. Canadian Journal of Physiology and Pharmacology 57: 600-605 (1979).
    17. Gross, D.M. and Fisher, J.W. Erythropoietic effects of PGE2 and two endoperoxide analogs. Experientia 36: 458-459 (1980).
    18. Sweet, C.S., Wenger, H.C., Taylor, D.A. and Gross, D.M. Central antihypertensive properties of muscimol and related structures. Brain Research Bulletin 5(2): 491-496 (1980).
    19. Patchett, A., Harris, E., Tristram, E., Wyratt, M., Wu, M.T., Taub,D., Peterson, E., Ikeler, T., ten Broeke, J., Payne, L. Ondeyka, D., Thorsett, E., Greenlee,W., Lohr, N., Hoffsommer, R., Joshua, H., Ruyle, W., Rothrock, J., Aster,S., Robinson, F.M., Hirschmann, R., Sweet, C.S., Ulm, E.H., Gross, D.M.,Vassil, T. and Stone, C.A. A new class of converting enzyme inhibitors. Nature 288: 280-283 (1980).
    20. Gross, D.M., Sweet, C.S., Ulm, E.H., Backlund, E.P., Morris, A.A., Weitz, D., Bohn, D.L., Wenger, H.C., Vassil, T.C. and Stone, C.A. Effect of N-(S-1-carboxy-3-phenylpropyl)-L-Ala-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme invitro and angiotensin I pressor responses in vivo.Journal of Pharmacology and ExperimentalTherapeutics 216: 552-557 (1981).
    21. Sweet, C.S., Gross, D.M.,Arbegast, P.T., Gaul, S.L., Britt, P.M., Ludden, C.T., Weitz, D. and Stone, C.A. Antihypertensive activity of N-{(S)-1-(ethoxycarbonyl)-3-phenylpropyl}-L-Ala-L-Pro (MK-421): an orally active converting enzyme inhibitor. Journal of Pharmacology and Experimental Therapeutics.216: 558-566 (1981).
    22. Sweet, C.S., Arbegast, P.T., Gaul, S.L., Blaine, E.H. and Gross, D.M. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. European Journal of Pharmacology 76: 167-176 (1981).
    23. Gross, D.M. and Weitz, D. An automated data acquisition system for isolatedinvitro tissue studies. Journal of Pharmacological Methods 8: 151-159 (1982).
    24. Baldwin, J.J., McClure, D.E., Gross, D.M. and Williams, M. Use of (S)-(Trifloxymethyl)oxirane in the synthesis of a chiral ß-adrenoceptor antagonist,(R)- and (S)-9- [[3-(tert-Butylamino)-2-hydroxypropyl]oximino] fluorine. Journal of Medicinal Chemistry .25: 931-936 (1982).
    25. McClure, D.E., Baldwin, J.J., Lyon, T.F., Mensler, K., Lundell, G.F., Raab, A.W., Gross, D.M., Risley, E.A., Sweet, C.S. and Williams, M. Antihypertensive ß-adrenergic blocking agents:N-aralkyl analogues of 2-[3-(tertButylamino)-2- hydroxypropoxy]-3-cyanopyridine. Journal of Medicinal Chemistry 26: 649-657 (1983).
    26. Baldwin, J.J., Denny, G.H., Hirschmann, R., Freeman, M.B., Ponticello, G.S., Gross, D.M. and Sweet, C.S. ß1 selective adrenoceptor antagonists: Examples of the 2-[4-(3-(Substituted-amino)-2-hydroxypropoxy)phenyl]amino]imidazole class. Journal of Medicinal Chemistry 26: 950-957 (1983).
    27. Schmitt, C.J., Gross, D.M. and Share, N.N. Beta-adrenergic receptor subtypes in iris-ciliary body of rabbits. Graefe's Archive of Clinical and Experimental Ophthalmology 221: 167-170 (1984)
    28. Share, N.N., Lotti, V.J., Gautheron, P., Schmitt, C., Gross,D.M.,Hall, R.A. and Stone, C.A. R-Enantiomer of timolol: a potential selective ocular antihypertensive agent. Graefe's Archive of Clinical and Experimental Ophthalmology 221: 234-238 (1984).
    29. Huang, L., Brown, G., Dunn, J., Sykes, R., Dobna, R. Mayler, R.A., Gross, D.M. and Burg, R.W. Discovery, purification and characterization of the angiotensin converting enzyme inhibitor, L-681,176, produced by Streptomyces Sp. MA 5143a. The Journal of Antibiotics 37: 462-465 (1984).
    30. Gross, D.M. Disks, Disks, Disks for the Laboratory: Security Aspects- A/C Interface. Analytical Chemistry 57(7): 810A-814A (1985).
    31. Gross, D.M. and Share, N.N. Beta-adrenergic receptor subtypes in iris-ciliary body of rabbits. Graefe's Archives of Clinical and Experimental Opthalmology 223: 168 (1985).
    32. Baldwin, J.J., Christy, M.E., Denny, G.H., Habecker, C.A., Freedman, M.B., Lyle, P.A., Ponticello, G.S., Varga, S.L., Gross, D.M., Sweet, C.S. ß1 selective adrenoceptor antagonists with and without beta-agonism: Examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy] phenyl]imidazole class. Journal of Medicinal Chemistry 29: 1065-1080 (1986).
    33. Klein, H., Gross, D.M., O'Beirne, A. and Nolan, T. Adaptation of a fluorescent immunoassay for canine haptoglobin. The Cornell Veterinarian 77: 21-32 (1987).
    34. Silverman, I.M., Dawicki-Mckenna, J.M., Frederick, D.W., Bialas, C., Remberg, J.R., Yohn, N.L.. Sekulic, N., Reitz, A.B. and Gross, D.M. Evaluating the Success of the Small Business Innovation Research (SBIR) Program: Impact on Biotechnology Companies in Pennsylvania. Technology Transfer and Entrepreneurship 2(2):4-13 (2015)
    35. Gross, D.M. Commentary: If you build it will they come? Real estate, the Lab and the Biopharma Outlook. Technology Transfer and Entrepreneurship 3(1):7-10 (2016)
    36. Gross, D.M. Preface to Volume 3. Technology Transfer and Entrepreneurship 3(1): 4 (2016)
    37. Bialas, C., Higbee-Dempsey, E., Chen, C.Y., Ward, C., Marcos-Contreras, O.A., Mulreany, D. Reitz, A.B. and Gross, D.M. Analyzing the FDA Priority Review Voucher Program's Stimulation of Research and Public Health Impact. Technology Transfer and Entrepreneurship 3(2): 131-141 (2016)
    38. Allenby, C.E. Babiash, E.S., Blank, P.N., Carpenter, M.D., Lee, I.G., Li, R.B., Robustelli, J., Zhu, Y., Gross, D.M. Analysis of the Market, Regulatory Landscape, and Current State of Clinical Trials Pertaining to Digital Health. Technology Transfer and Entrepreneurship 5(1): 21-34 (2018)

Theses/Book Chapters/Proceedings/Book Reviews/Research Reports

  1. Gross, D.M. "Tissue Fractionations in Reorienting Density Gradients" Master's Thesis, California State University, Northridge, x + 142 pages, (1970).
  2. Gross, D.M. "The Isolation and Characterization of Renin-Containing Granules from Rabbit Renal Cortex" Doctoral Dissertation, University of California, Los Angeles, xi + 210 pages, Published by University Microfilms, Ann Arbor, MI, copyright (1974).
  3. Fisher, J.W. and Gross, D.M. "Renal Prostaglandins and Kidney Production of Erythropoietin" in Kidney Hormones-Erythropoietin, Volume II edited by James W. Fisher, Academic Press, London, pp. 357-385, (1977).
  4. Fisher, J.W. and Gross, D.M. "Hormonal Influences on Erythropoiesis: Anterior Pituitary, Adrenocortical, Thyroid, Growth and other Hormones" in Kidney Hormones-Erythropoietin, Volume II, edited by James W. Fisher, Academic Press, pp. 415-435, (1977)
  5. Gross, D.M. ,Pavlovic-Kentera, V. and Pavlov, A.V. "Recent Advances in Erythropoietin Research in the Soviet Union" in Kidney Hormones- Erythropoietin, Volume II, edited by James W. Fisher, Academic Press, London, pp 585-590, (1977).
  6. Fisher, J.W. and Gross, D.M. "Effects of Prostaglandins on Erythropoiesis" in Prostaglandins in Hematology: Proceedings of the First International Symposium on Prostaglandins in Hematology edited by M.J. Silver, J.B. Smith and J.J. Kocsis, Spectrum Press, New York, pp. 159-185, (1977).
  7. Fisher, J.W., Gross, D.M., Foley, J.E. and Jubiz, W. "A Concept for the Role of Prostaglandins in Kidney Production of Erythropoietin" in Proceedings of the 16th.International Congress of Hematology, University Park Press, Baltimore, Tokyo, (1977).
  8. Fisher, J.W., Gross, D.M., Foley, J.E., Nelson, P.K., Rodgers, G.M., George, W.J. and Jubiz, W. "A Concept for the Control of Kidney Production of Erythropoietin Involving Prostaglandins and Cyclic Nucleotides" in Proceedings of the5th. Hannover Nephrology Symposium in Non-Vasoactive Renal Hormones, edited by G.M. Eisenbach and J. Brod, Volume 13 of Contributions to Nephrology, pp. 37-59, Karger, Basel, (1978).
  9. Fisher, J.W., Ohno, Y., Modder, B., Przala, F., Fink, G.D., and Gross, D.M. "Pharmacological Agents and Erythroid Colony Formation: Effects of Beta-Adrenergic Agonists and Steroids" in InVitro Aspects of Erythropoiesis, edited by M.J. Murphy, pp. 103-117, Springer-Verlag, New York, (1978).
  10. Fisher, J.W., Ohno, Y., Modder, B., Przala, F., Fink, G.D. and Gross, D.M. "Plasma Clot Erythroid Colony-Forming Cell Bone Marrow Culture Technique" in In Vitro Aspects of Erythropoiesis, Appendix 2, edited by M.J. Murphy, pp. 246-247, Springer-Verlag, New York, (1978).
  11. Sweet, C.S., Wenger, H.C., Taylor, D.A. and Gross, D.M. "Central Antihypertensive Properties of Muscimol and Related Structures" in Proceedings of the International Symposium on GABA and Other Inhibitory Neurotransmitters: GABA Neurotransmission- Current Developments in Physiology and Neurochemistry edited by H. Lal, S. Fielding, J. Malick, E. Roberts, N. Shah and E. Usdin. Brain Research Bulletin Vol. 5, Supplement 2, pp. 491-496, (1980).
  12. Sweet, C.S., Britt, P.M., Solar, J.J., Arbegast, P.T. and Gross, D.M. "Peripheral Vascular Interactions of Timolol and Other Beta-Adrenoceptor Antagonists in Anesthetized Dogs" in Proceedings of the Timolol Intercontinental Symposium edited by L. Hansson, S. Julius and P.J. Richardson, Biomedical Information Corp., New York, pp. 111-130, (1981).
  13. Baldwin, J.J., Mensler, K., Lyon, T.F., Randall, W.C., Gross, D.M. and McClure, D.E. "The Influence of Chirality on Binding to the Alpha1-Adrenergic Receptor" in Proceedings of the VIII International Symposium on Medicinal Chemistry, Pergamon Press, Ltd., London, (1981).
  14. Sweet, C.S., Gross, D.M., Blaine, E.H., Ulm, E.H. and Stone, C.A. "A New Class of Converting Enzyme Inhibitors" in Proceedings of the International Symposium on New Trends in Arterial Hypertension, Cellular Pharmacology and Physiology, edited by M. Worcell, Elsevier/North Holland Biomedical Press, Amsterdam, pp. 263-277, (1981).
  15. Gross, D.M. "Applications of a Computer System to a Biological Research Laboratory" in The Merck Information World: Proceedings of the Second Colloquium, edited by E.W. Armstrong, Merck & Co., Inc. , pp. 112-117, (1982).
  16. Sweet, C.S., Patchett, A.A., Ulm, E.H. and Gross, D.M. "SAR Studies with ACE Inhibitors Related to Enalapril and MK-521" in Proceedings of the 2nd. SCI-RSC Medicinal Chemistry Symposium, Edited by J.C. Emmett, Royal Society of Chemistry, pp. 36-46, Special Publication No. 50, (1984).
  17. Solomon, H., Yeh, K.C., Gross, D.M. and Wase, A.W. "Comparison of Internal Dosimetry Estimation of the MIRD, Classical and Computer Application." Proceedings of the 17th. Midyear Topical Meeting of the Health Physics Society- Computer Applications in Health Physics, edited by R.L. Kathren, D.P. Higby and M.A. McKinney, Columbia Chapter of the Health Physics Society, 7.167-7.171, (1984).
  18. Baldwin, J.J., Christy, M.E., Denny, G.H., Freedman, M.B., Gross, D.M., Habecker, C.N., Lyle, P.A., Ponticello, G.S., Sweet, C.S., Varga, S.L. Beta1-selective adrenoceptor antagonists without intrinsic sympathomimetic activity. Proceedings of the Medicinal Chemistry 8th. International Symposium, Stockholm, Sweden, (1984).
  19. Gross, D.M. "Security: Disks for the Laboratory" in The Electronic Laboratory- Tutorials and Case Histories in Laboratory Automation, pp. 144-146, edited by R. E. Dessy, American Chemical Society, (1985), Washington, D.C.
  20. Gross, D.M. Book Review of "Famous Experiments You Can Do" by Robert Gardner. Appraisal-Science Books for Young People 24 (2/3): 13-15 (1991).
  21. Gross, D.M. Book Review of "Sensational Science Activities with Doctor Zed" by Gordon Penrose. Appraisal- Science Books for Young People 24 (2/3): 39-40 (1991).
  22. Fasciolo, J.C., Editor, Enalapril: The Landmark Papers, Science Press, London, (1991). Containing-Patchett, A., Harris, E., Tristram, E., Wyratt, M., Wu, M.T., Taub, D., Peterson, E., Ikeler, T., ten Broeke, J., Payne, L., Ondeyka, D., Thorsett, E., Greenlee, W., Lohr, N., Hoffsommer, R., Joshua, H., Ruyle, W., Rothrock, J., Aster, S., Robinson, F.M., Hirschmann, R., Sweet, C.S., Ulm, E.H., Gross, D.M.,Vassil, T. and Stone, C.A. A new class of converting enzyme inhibitors. Nature 288: 280-283 (1980).
  23. Gross, D.M. Book Review of "Blinkers and Buzzers: Building and Experimenting with Electricity and Magnetism" by Bernie Zubrowski. Appraisal-Science Books for Young People 25(1): 66-67 (1992).
  24. Gross, D.M. Book Review of "Sexually Transmitted Diseases" by Alan E. Nourse. Appraisal-Science Books for Young People 25(3): 45-46 (1992).
  25. Gross, D.M. Book Review of "Let's Talk About Series: Disabled People & What It's Like to be Old." by Peter Sanders. Appraisal-Science Books for Young People 26(2-3): 96-97 (1993)
  26. Gross, D.M. Book Review of "Charles Darwin: Revolutionary Biologist" by J. Edward Evans. Appraisal-Science Books for Young People 26(4): 19-20 (1993).
  27. Gross, D.M. Book Review of "Computer Crime: Phreaks, Spies, and Salami Slicers" by Kare Kudson. Appraisal- Science Books for Young People 27:(2-3): 21-22 (1994).
  28. Gross, D.M. Book Review of "Understanding Illness" Series by Elaine Landau. Appraisal- Science Books for Young People 28 (1): 118-119 (1995).
  29. Gross, D.M. Book Review of "Steve Wozniak: Inventor of the Apple Computer" by Martha E. Kendall. Appraisal- Science Books for Young People 28:(4): 28 (1995).
  30. Gross, D.M. Book Review of "Coyotes in the Crosswalk: True Tales of Animal Life in the Wilds of the City" by Diane Swanson. Appraisal- Science Books for Young People 29 (1-2): 60-61 (1996).
  31. Gross, D.M. Book Review of "Alternative Medicine: Cures or Myths" by Facklam, Howard. Appraisal - Science Books for Young People 30 (1-2):16-17 (1997).
  32. Gross, D.M. Book Review of "Whales, Dolphins and Porpoises" by Mark Carwardine, Erich Hoyt, R. Ewan Fordyce, and Peter Gill. Appraisal - Science Books for Young People 32 (1):12 (1999).
  33. Gross, D.M. Book Review of “Always Inventing: A Photobiography of Alexander Graham Bell by Tom L. Matthews. Appraisal – Science Books for Young People 33 (2-4): Online (2000).
  34. Gross, D.M. Book Review of “Famous Problems and Their Mathematicians” by Art Johnson. Appraisal – Science Books for Young People 33 (2-4): Online (2000).
  35. Gross, D.M. Book Review of “The Elements Series: Hydrogen, Magnesium, Gold” by John Farndon, Appraisal – Science Books for Young People 33 (2-4): Online (2000)
  36. Gross, D.M. Book Review of “Made in China: Ideas and Inventions from Ancient China” by Suzanne Williams, Appraisal – Science Books for Young People 34(2): Online (2001).
  37. Gross, D.M. Book Review of “Bloody Moments” by Gael Jennings, Appraisal – Science Books for Young People 34(2): Online (2001).
  38. Gross, D.M. Book Review of “Vanishing From the Skies” and Vanishing From the Waterways” By Gail Radley, Illustrated by Jean Sherlock, Appraisal – Science Books for Young People 35(1):Online (2002).
  39. Gross, D.M., Mullen, S. and Cavallero, A. “Merck Research Laboratories – Boston” in Buildings of Massachusetts: Metropolitan Boston as part of a 58-volume series sponsored by the Society of Architectural Historians entitled Buildings of the United States, Edited by Keigh N. Morgan Oxford University Press (2005).
  40. Carpenter, W., Coleman, K., Critchley, I.A., Goldberg, R., Gross, D.M., Hunter-Cevera, J., Robertson, G., Stimson, A.E., “Resuscitating the Bioweapons Ban: U.S. Industry Experts’ Plans for Treaty Monitoring- A Collaborative Research Report of Experts from the U.S. Pharmaceutical and Biotechnology Industries. The Center for Strategic& International Studies, Washington, D.C. (2004).
  41. Gross, D.M. "Will that be hollandaise with your eggs, or a side of vaccine?" Health Outcomes Communicator: Posted 11 December 2009 (Online Publication).
  42. Gross, D.M. “Design and Operation of the Sustainable Laboratory Building: Considerations and Musings” in Sustainable Design of Research Laboratories: Planning, Design, and Operations edited by Neilson, J., Sisle, E., Leary, C., Weiss, J. and Leonard. P., Wiley& Sons, Inc., New York (2010).
  43. Gross, D.M. Book review of “Getting Change Right: How Leaders Transform Organizations From the Inside Out.” Management Matters 3(1):1,5 (2012).
  44. Gross, D.M. "The FDA Priority Review Voucher System" The PDDI Newsletter 5:1 (2015)
  45. Gross, D.M. "2014: The FDA CDER Year in Review - Themes and Challenges" The PDDI Newsletter 5:2(2015)
  46. Gross, D.M. "Quantifying Biomarkers' Impact on Drug Development" The PDDI Newsletter 6:2 (2016)
  47. Gross, D.M. "Continuous Drug Manufacturing: The Future or a Burden?" The PDDI Newsletter 6:3 (2016)
  48. Chu, J.C., DiProspero, D., Matje, R.E. and the ISPE Oral Solid Dosage Community of Practice (OSD COP) "ISPE Baseline Pharmaceutical Engineering Guide: Volume 2 Oral Solid Dosage Forms, 3rd Edition", ISPE 2016
  49. Gross, D.M. “Preface: Thematic Issue on Entrepreneurial Ecosystems – Part II”, Technology Transfer and Entrepreneurship, 6(1): 4 (2019)

The online JS minimizer tool helps you optimize your scripts for a better page loading speed.

profile

Ismael J. Hidalgo, Ph.D.

Chief Scientific Officer
Absorption Systems, Exton, PA

Education:
• B.S., Pharmacy, Panama

  • Ph.D., Pharmaceutical Sciences, University of Southern California
  • Postdoctoral Fellow, Department of Pharmaceutical Chemistry, University of Kansas

Post-Graduate Training

  • Postdoctoral Fellow, Department of Pharmaceutical Chemistry, University of Kansas

Past Professional Experience

  • SmithKline Beecham
  • Rhrone-Poulenc Rorer

Dr. Ismael Hidalgo is widely recognized as the pioneer of the Caco-2 cell line for studying intestinal epithelial membrane permeability. His seminal paper “Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability” has been cited nearly 2,000 times since its publication in 1989 in the journal Gastroenterology.

He co-founded Absorption Systems in 1996. Absorption Systems began in Exton, PA, and has now expanded to have additional sites in Panama and San Diego, CA. They offer a large panel of services for pharmaceutical companies, ranging from drug transport assays to toxicology.

Dr. Hidalgo’s most recent work is in dissolution and permeation profiles of nano- and micro-sized formulations of drugs using a novel dissolution absorption system. He has also recently reported findings related to the influence of excipients on permeability of BCS Class III compounds.

View Dr. Hidalgo's publications on Google Scholar

profile

Prakash Manikwar, Ph.D.

Scientist II at AstraZeneca
Gaithersburg, Maryland

Education:
•Ph.D., Pharmaceutical Chemistry, The University of Kansas

  • M.S., Pharmaceutical Sciences, South Dakota State University
  • B. Pharm., J.S.S. College of Pharmacy, Rajiv Gandhi University of Health Sciences

Scientist II, AstraZeneca, Gaithersburg, MD
Scientist I, MedImmune, Gaithersburg, MD
Post-doctoral fellow, Macromolecular and Vaccine Stabilization Center, University of Kansas

Dr. Prakash Manikwar is a pharmaceutical scientist with extensive experience in formulation development, biophysical and analytical characterization of complex therapeutic proteins. He has technical and strategic CMC expertise in early stage development and process engineering of biological drug products. He has a keen interest in learning and applying new concepts and technologies. His goal is to utilize his skills in the field of formulation of biologics to support and lead product development. He enjoys taking on new and exciting challenges in a fast pace and dynamic research environment.

Research Interests
Biotechnology, formulation and process development, proteins (such as monoclonal antibody, ADC, bispecific antibody and fusion proteins), biophysics, and spectroscopy.

View Dr. Manikwar’s publications on Google Scholar

profile

Douglas H. Sweet, Ph.D.

Chair of Pharmaceutics, Virginia Commonwealth University
E. Claiborne Robins Distinguished Professor

Education:
• B.S., Biology (University of Michigan, 1984)

  • M.S., Biology (University of Michigan, 1987)
  • Ph.D., Biology (University of Michigan, 1993)

Post-Graduate Training

  • Post Doctoral Fellow - DNA Repair Mechanisms (Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill (1993-, 1995)
  • Intramural Research Training Fellow - Renal Organic Solute Transport (Laboratory of Pharmacology and Chemistry, Renal Pharmacology Section, NIH/NIEHS (1995-, 2000)

Professional Experience

  • (2015 - Present) Professor and Chair, Department of Pharmaceutics, Virginia Commonwealth University
  • (2008 - 2015) Associate Professor, Department of Pharmaceutics, Virginia Commonwealth University
  • (2007 - 2008) Associate Professor, Department of Pharmaceutical Sciences, Medical University of South Carolina
  • (2002 - 2007) Assistant Professor, Department of Pharmaceutical Sciences, Medical University of South Carolina
  • (2000 - 2002) Assistant Project Scientist, Department of Medicine/Nephrology, University of California, San Diego

Professional and Scholarly Interests
Comparative Physiology and Toxicology of Epithelial Transport

Research Interests
Organisms encounter a diverse array of potentially hazardous substances on a daily basis, including medications, plant and animal toxins, and products of cellular metabolism. An individual's ability to survive these exposures greatly depends upon the efficiency of the excretory and detoxifying organs of the body (e.g., liver, kidney, choroid plexus). Our research focus is on the proteins responsible for the transport of organic solutes in renal proximal tubule, choroid plexus, and brain capillary endothelium. Understanding the mechanisms these transporters utilize to protect the body and brain from fluctuations in the composition of the blood and cerebrospinal fluid will provide unique insight into toxicity, drug-drug interaction, and human disease states. We use Xenopus oocyte, cell culture, intact tissue, and knockout mouse model systems to: (1) determine the energetics and specificity of the transporters, (2) define the roles of transporters in drug interactions and disease, and (3) identify the mechanisms involved in the modulation of transporter function and expression.

View Dr. Sweets’s publications on Google Scholar


©